25 research outputs found
Use of radiographic and histologic scores to evaluate cats with idiopathic megacolon grouped based on the duration of their clinical signs
Since the duration of clinical signs could be used to identify cases of chronic constipation, in addition, prolonged duration is often associated with irreversible changes. Thus, the main objective of this study was to determine whether the duration of clinical signs of idiopathic megacolon in cats affected their diagnosis and prognosis after treatment. Medical records of cats that either had confirmed megacolon for an unknown cause (cat patients) or with normal bowels (control cats) were reviewed. Cat patients were grouped based on the duration of their clinical signs (constipation/obstipation) to cats <6 months and ≥6 months. For all feline patients, abdominal radiographs (for colonic indexes) and resected colon specimens (for histology) were assessed vs. control cats. Treatment applied to cat patients was also evaluated. Cat patients were older (p = 0.0138) and had a higher maximum colon diameter (MCD; mean 41.25 vs. 21.67 mm, p < 0.0001) and MCD/L5L ratio (1.77 vs. 0.98, p < 0.0001) than controls. Compared to cats with <6 months, cats ≥6 months showed a higher MCD (43.78 vs. 37.12 mm, p < 0.0001) and MCD/L5L ratio (1.98 vs. 1.67, p < 0.0001). Histologically, increased thickness of the smooth muscularis mucosa (54.1 vs. 22.33 μm, p < 0.05), and inner circular (743.65 vs. 482.67 μm, p < 0.05) and outer longitudinal (570.68 vs. 330.33 μm, p < 0.05) smooth muscular layers of the muscularis externa was noted only in cat patients with ≥6 months compared to controls. Similarly, fewer ganglion cells (0.93 vs. 2.87, p < 0.005) and more necrotized myocytes (2.25 vs. 0.07, p < 0.005) were observed in cats with ≥6 months. In contrast to <6 months, the majority of cats (94.4%) with ≥6 months duration did not show any response to medical treatment and therefore underwent surgery with favorable results. In conclusion, this study suggests that the duration of clinical signs should be considered in conjunction with maximal colon scores to evaluate cats for idiopathic megacolon and determine the level of treatment. Functional abnormalities of the colonic smooth muscles may be a possible cause of idiopathic megacolon in cats
Consensus Middle East and North Africa Registry on Inborn Errors of Immunity
Background: Inborn errors of immunity (IEIs) are a heterogeneous group of genetic defects of immunity, which cause high rates of morbidity and mortality mainly among children due to infectious and non-infectious complications. The IEI burden has been critically underestimated in countries from middle- and low-income regions and the majority of patients with IEI in these regions lack a molecular diagnosis. Methods: We analyzed the clinical, immunologic, and genetic data of IEI patients from 22 countries in the Middle East and North Africa (MENA) region. The data was collected from national registries and diverse databases such as the Asian Pacific Society for Immunodeficiencies (APSID) registry, African Society for Immunodeficiencies (ASID) registry, Jeffrey Modell Foundation (JMF) registry, J Project centers, and International Consortium on Immune Deficiency (ICID) centers. Results: We identified 17,120 patients with IEI, among which females represented 39.4%. Parental consanguinity was present in 60.5% of cases and 27.3% of the patients were from families with a confirmed previous family history of IEI. The median age of patients at the onset of disease was 36Â months and the median delay in diagnosis was 41Â months. The rate of registered IEI patients ranges between 0.02 and 7.58 per 100,000 population, and the lowest rates were in countries with the highest rates of disability-adjusted life years (DALY) and death rates for children. Predominantly antibody deficiencies were the most frequent IEI entities diagnosed in 41.2% of the cohort. Among 5871 patients genetically evaluated, the diagnostic yield was 83% with the majority (65.2%) having autosomal recessive defects. The mortality rate was the highest in patients with non-syndromic combined immunodeficiency (51.7%, median age: 3.5Â years) and particularly in patients with mutations in specific genes associated with this phenotype (RFXANK, RAG1, and IL2RG). Conclusions: This comprehensive registry highlights the importance of a detailed investigation of IEI patients in the MENA region. The high yield of genetic diagnosis of IEI in this region has important implications for prevention, prognosis, treatment, and resource allocation
SARS-CoV-2 susceptibility and COVID-19 disease severity are associated with genetic variants affecting gene expression in a variety of tissues
Variability in SARS-CoV-2 susceptibility and COVID-19 disease severity between individuals is partly due to
genetic factors. Here, we identify 4 genomic loci with suggestive associations for SARS-CoV-2 susceptibility
and 19 for COVID-19 disease severity. Four of these 23 loci likely have an ethnicity-specific component.
Genome-wide association study (GWAS) signals in 11 loci colocalize with expression quantitative trait loci
(eQTLs) associated with the expression of 20 genes in 62 tissues/cell types (range: 1:43 tissues/gene),
including lung, brain, heart, muscle, and skin as well as the digestive system and immune system. We perform
genetic fine mapping to compute 99% credible SNP sets, which identify 10 GWAS loci that have eight or fewer
SNPs in the credible set, including three loci with one single likely causal SNP. Our study suggests that the
diverse symptoms and disease severity of COVID-19 observed between individuals is associated with variants across the genome, affecting gene expression levels in a wide variety of tissue types
Whole-genome sequencing reveals host factors underlying critical COVID-19
Critical COVID-19 is caused by immune-mediated inflammatory lung injury. Host genetic variation influences the development of illness requiring critical care1 or hospitalization2–4 after infection with SARS-CoV-2. The GenOMICC (Genetics of Mortality in Critical Care) study enables the comparison of genomes from individuals who are critically ill with those of population controls to find underlying disease mechanisms. Here we use whole-genome sequencing in 7,491 critically ill individuals compared with 48,400 controls to discover and replicate 23 independent variants that significantly predispose to critical COVID-19. We identify 16 new independent associations, including variants within genes that are involved in interferon signalling (IL10RB and PLSCR1), leucocyte differentiation (BCL11A) and blood-type antigen secretor status (FUT2). Using transcriptome-wide association and colocalization to infer the effect of gene expression on disease severity, we find evidence that implicates multiple genes—including reduced expression of a membrane flippase (ATP11A), and increased expression of a mucin (MUC1)—in critical disease. Mendelian randomization provides evidence in support of causal roles for myeloid cell adhesion molecules (SELE, ICAM5 and CD209) and the coagulation factor F8, all of which are potentially druggable targets. Our results are broadly consistent with a multi-component model of COVID-19 pathophysiology, in which at least two distinct mechanisms can predispose to life-threatening disease: failure to control viral replication; or an enhanced tendency towards pulmonary inflammation and intravascular coagulation. We show that comparison between cases of critical illness and population controls is highly efficient for the detection of therapeutically relevant mechanisms of disease
Recommended from our members
Using Functional Genomics to Understand Physiological Processes and Injury Response in Human Erythroid Cells
The vital roles of red blood cells (RBCs) underscore the importance of functional and homeostatic cellular processes in erythroid precursors. Iron acquisition and trafficking by erythroid cells is a key physiological process for their survival, proliferation and differentiation. In contrast, exposure to hematotoxicants can deplete erythroid precursors or disrupt erythroid differentiation. Complete elucidation of mechanisms relevant to a biological process or response to an injury in erythroid cells can improve our understanding of the pathophysiology and etiology of RBC disorders. Interrogating the genome in the context of a cellular process is a key strategy to understand underlying molecular mechanisms. Comprehensive identification of pathways governing physiological as well as injurious cellular processes has become more feasible due to the emergence of genome-wide functional genomic approaches. Recently, the CRISPR-Cas9 system has revolutionized the field of functional genomics as it enabled simple, efficient and cost-effective platforms for large-scale genetic screening. In this series of studies, CRISPR-based genome-wide loss-of function screening was employed to identify genes and pathways contributing to erythroid key processes including iron uptake, heme trafficking and erythroid differentiation, as well as response to hematotoxicants.Chapter 1 reviews the various CRISPR-Cas9 screening platforms and their applications in functional genomics. Different screening strategies using large-scale loss-of-function and gain-of-function approaches are compared in terms of their effectiveness, feasibility, and suitability to study particular cellular processes. Steps of pooled screening, data analysis methods and hit validation strategies are described and critical technical considerations are addressed. In addition, the power of CRISPR-based genetic screening in different research fields including basic cell biology, cancer, drug discovery, pharmacogenomics and toxicogenomics is demonstrated. Finally, limitations of the current CRISPR screening platforms are revised and strategies for improvement are proposed.In chapter 2, a genome-wide CRISPR-based screen designed to study iron uptake in erythroid cells is described. The physiological iron form, transferrin-bound iron (TBI), is taken up by erythroid cells through the transferrin receptor (TfR) by endocytosis. Non-transferrin bound iron (NTBI), which is present in the circulation during iron overload, can also be acquired by erythroid cells. Uncontrolled cellular NTBI influx can result in iron toxicity. To identify molecular determinants of TBI and NTBI uptake, a genome-wide loss-of-function screen was performed in human K562 erythroleukemic cells which can utilize both TBI and NTBI to grow and proliferate. The screen revealed multiple genes whose disruption resulted in defective growth when either TBI or NTBI is the exclusive source of iron. Unsurprisingly, TBI uptake candidates included the transferrin receptor (TfR1) in addition to several components of the endocytic pathway. Follow up studies on one candidate, CCDC115, confirmed its role in cellular TBI uptake. CCDC115 is a V-ATPase assembly factor and its role in endosomal acidification likely underlies its function in transferrin iron influx.In chapter 3, a genome-wide knockout screen investigating cellular mechanisms of heme trafficking and heme-induced erythroid differentiation is documented. Under physiological conditions, heme is synthesized in the mitochondria of erythroid cells where it plays structural as well as functional roles in erythroid differentiation. Additionally, erythroid cells are capable of taking up extracellular heme which might be utilized in pathological forms of erythropoiesis or could induce toxicity in the absence of other erythropietic signals. Heme treatment of K562 erythroleukemic cells induces erythroid differentiation resulting in a proliferation block. The screen was designed to identify genes whose inactivation alleviates the heme-induced proliferation block. The identified candidates include components of the clathrin-mediated endocytosis and vesicle acidification pathways in addition to epigenetic and RNA processing regulators. Intriguingly, the V-ATPase assembly factor CCDC115 was among the top candidates. Analysis of CCDC115 deficient cells unveiled an unprecedented role of CCDC115 in cellular heme uptake. Gene products whose loss results in heme-induced toxicity were also identified and included the heme oxygenase HMOX2, other detoxification enzymes and members of the ABC transporter family. Chapter 4 reports identification of cellular mechanisms that modulate erythroid cell sensitivity to arsenic trioxide (ATO), a potent hematotoxicant and an effective anti-leukemic agent. A genome-wide loss-of-function CRISPR-based screen revealed novel molecular components influencing susceptibility of K562 erythroleukemic cells to ATO. Many of the candidates identified in the primary screen were simultaneously validated in a secondary screening approach. Functional enrichment analysis of validated genes revealed multiple pathways/processes implicated in the cellular response to ATO. The most significant pathway controls biosynthesis of selenocysteine, the 21st amino acid, and its incorporation into selenoproteins. Inactivation of components of this pathway resulted in notable cellular resistance to ATO. Based on the screening results, two models explaining the role of selenocysteine metabolism in ATO toxicity were proposed: the compromised thioredoxin reductase model and the arsenic-selenium-glutathione export model. Intriguingly, selenium pre-treatment of cells exhibited a protective effect against ATO cytotoxicity.In chapter 5, susceptibility of erythroid cells to another hematotoxicant, acetaldehyde, was studied. Acetaldehyde, the primary product of alcohol metabolism and an endogenous metabolite, is a potential carcinogen and its well-established genotoxicity is thought to underlie bone marrow failure in Fanconi Anemia. A genome-wide knockout screen in erythroleukemic K562 cells identified several determinants of sensitivity to acetaldehyde. Consistent with the documented role of aldehydes in DNA damage, multiple identified candidate genes encode DNA repair enzymes. The top candidate gene encodes the tumor suppressor OVCA2, whose function is unknown. The uncovered role of OVCA2 in detoxifying acetaldehyde was validated in a secondary screen and by individual disruption of the OVCA2 gene. Interestingly, OVCA2 deficient cells displayed increased accumulation of the acetaldehyde-derived DNA adduct N2-ethylidene-2G. Overall, these studies demonstrated the effectiveness of CRISPR/Cas9 loss-of-function genetic screening in deciphering mechanisms relevant to erythroid cell survival, proliferation, differentiation and response to injury
Recommended from our members
Using Functional Genomics to Understand Physiological Processes and Injury Response in Human Erythroid Cells
The vital roles of red blood cells (RBCs) underscore the importance of functional and homeostatic cellular processes in erythroid precursors. Iron acquisition and trafficking by erythroid cells is a key physiological process for their survival, proliferation and differentiation. In contrast, exposure to hematotoxicants can deplete erythroid precursors or disrupt erythroid differentiation. Complete elucidation of mechanisms relevant to a biological process or response to an injury in erythroid cells can improve our understanding of the pathophysiology and etiology of RBC disorders. Interrogating the genome in the context of a cellular process is a key strategy to understand underlying molecular mechanisms. Comprehensive identification of pathways governing physiological as well as injurious cellular processes has become more feasible due to the emergence of genome-wide functional genomic approaches. Recently, the CRISPR-Cas9 system has revolutionized the field of functional genomics as it enabled simple, efficient and cost-effective platforms for large-scale genetic screening. In this series of studies, CRISPR-based genome-wide loss-of function screening was employed to identify genes and pathways contributing to erythroid key processes including iron uptake, heme trafficking and erythroid differentiation, as well as response to hematotoxicants.Chapter 1 reviews the various CRISPR-Cas9 screening platforms and their applications in functional genomics. Different screening strategies using large-scale loss-of-function and gain-of-function approaches are compared in terms of their effectiveness, feasibility, and suitability to study particular cellular processes. Steps of pooled screening, data analysis methods and hit validation strategies are described and critical technical considerations are addressed. In addition, the power of CRISPR-based genetic screening in different research fields including basic cell biology, cancer, drug discovery, pharmacogenomics and toxicogenomics is demonstrated. Finally, limitations of the current CRISPR screening platforms are revised and strategies for improvement are proposed.In chapter 2, a genome-wide CRISPR-based screen designed to study iron uptake in erythroid cells is described. The physiological iron form, transferrin-bound iron (TBI), is taken up by erythroid cells through the transferrin receptor (TfR) by endocytosis. Non-transferrin bound iron (NTBI), which is present in the circulation during iron overload, can also be acquired by erythroid cells. Uncontrolled cellular NTBI influx can result in iron toxicity. To identify molecular determinants of TBI and NTBI uptake, a genome-wide loss-of-function screen was performed in human K562 erythroleukemic cells which can utilize both TBI and NTBI to grow and proliferate. The screen revealed multiple genes whose disruption resulted in defective growth when either TBI or NTBI is the exclusive source of iron. Unsurprisingly, TBI uptake candidates included the transferrin receptor (TfR1) in addition to several components of the endocytic pathway. Follow up studies on one candidate, CCDC115, confirmed its role in cellular TBI uptake. CCDC115 is a V-ATPase assembly factor and its role in endosomal acidification likely underlies its function in transferrin iron influx.In chapter 3, a genome-wide knockout screen investigating cellular mechanisms of heme trafficking and heme-induced erythroid differentiation is documented. Under physiological conditions, heme is synthesized in the mitochondria of erythroid cells where it plays structural as well as functional roles in erythroid differentiation. Additionally, erythroid cells are capable of taking up extracellular heme which might be utilized in pathological forms of erythropoiesis or could induce toxicity in the absence of other erythropietic signals. Heme treatment of K562 erythroleukemic cells induces erythroid differentiation resulting in a proliferation block. The screen was designed to identify genes whose inactivation alleviates the heme-induced proliferation block. The identified candidates include components of the clathrin-mediated endocytosis and vesicle acidification pathways in addition to epigenetic and RNA processing regulators. Intriguingly, the V-ATPase assembly factor CCDC115 was among the top candidates. Analysis of CCDC115 deficient cells unveiled an unprecedented role of CCDC115 in cellular heme uptake. Gene products whose loss results in heme-induced toxicity were also identified and included the heme oxygenase HMOX2, other detoxification enzymes and members of the ABC transporter family. Chapter 4 reports identification of cellular mechanisms that modulate erythroid cell sensitivity to arsenic trioxide (ATO), a potent hematotoxicant and an effective anti-leukemic agent. A genome-wide loss-of-function CRISPR-based screen revealed novel molecular components influencing susceptibility of K562 erythroleukemic cells to ATO. Many of the candidates identified in the primary screen were simultaneously validated in a secondary screening approach. Functional enrichment analysis of validated genes revealed multiple pathways/processes implicated in the cellular response to ATO. The most significant pathway controls biosynthesis of selenocysteine, the 21st amino acid, and its incorporation into selenoproteins. Inactivation of components of this pathway resulted in notable cellular resistance to ATO. Based on the screening results, two models explaining the role of selenocysteine metabolism in ATO toxicity were proposed: the compromised thioredoxin reductase model and the arsenic-selenium-glutathione export model. Intriguingly, selenium pre-treatment of cells exhibited a protective effect against ATO cytotoxicity.In chapter 5, susceptibility of erythroid cells to another hematotoxicant, acetaldehyde, was studied. Acetaldehyde, the primary product of alcohol metabolism and an endogenous metabolite, is a potential carcinogen and its well-established genotoxicity is thought to underlie bone marrow failure in Fanconi Anemia. A genome-wide knockout screen in erythroleukemic K562 cells identified several determinants of sensitivity to acetaldehyde. Consistent with the documented role of aldehydes in DNA damage, multiple identified candidate genes encode DNA repair enzymes. The top candidate gene encodes the tumor suppressor OVCA2, whose function is unknown. The uncovered role of OVCA2 in detoxifying acetaldehyde was validated in a secondary screen and by individual disruption of the OVCA2 gene. Interestingly, OVCA2 deficient cells displayed increased accumulation of the acetaldehyde-derived DNA adduct N2-ethylidene-2G. Overall, these studies demonstrated the effectiveness of CRISPR/Cas9 loss-of-function genetic screening in deciphering mechanisms relevant to erythroid cell survival, proliferation, differentiation and response to injury
A Cloud-based Malware Detection Framework
Malwares are increasing rapidly. The nature of distribution and effects of malwares attacking several applications requires a real-time response. Therefore, a high performance detection platform is required. In this paper, Hadoop is utilized to perform static binary search and detection for malwares and viruses in portable executable files deployed mainly on the cloud. The paper presents an approach used to map the portable executable files to Hadoop compatible files. The Boyer–Moore-Horspool Search algorithm is modified to benefit from the distribution of Hadoop. The performance of the proposed model is evaluated using a standard virus database and the system is found to outperform similar platforms